NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Read More…
Industry, Sector and Symbol
Industry Testing laboratories
Sub-IndustryN/A
SectorMedical
Phone239-768-0600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$276.74 million
Profitability
Miscellaneous
Employees1,500
Next Earnings Date10/29/2019 (Confirmed)
OptionableOptionable
NeoGenomics (NASDAQ:NEO) Frequently Asked Questions
What is NeoGenomics' stock symbol?
NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."
How were NeoGenomics' earnings last quarter?
NeoGenomics, Inc. (NASDAQ:NEO) released its quarterly earnings results on Tuesday, July, 30th. The medical research company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.05 by $0.02. The medical research company earned $101.71 million during the quarter, compared to analyst estimates of $97.32 million. NeoGenomics had a net margin of 0.57% and a return on equity of 4.97%. The company's quarterly revenue was up 50.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.05 earnings per share. View NeoGenomics' Earnings History.
When is NeoGenomics' next earnings date?
How can I listen to NeoGenomics' earnings call?
NeoGenomics will be holding an earnings conference call on Tuesday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has NeoGenomics issued on next quarter's earnings?
NeoGenomics issued an update on its FY 2019 earnings guidance on Tuesday, July, 30th. The company provided earnings per share (EPS) guidance of $0.23-0.27 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.26. The company issued revenue guidance of $388-402 million, compared to the consensus revenue estimate of $393.32 million.
What price target have analysts set for NEO?
7 analysts have issued 12-month price targets for NeoGenomics' stock. Their forecasts range from $15.00 to $30.00. On average, they expect NeoGenomics' stock price to reach $24.57 in the next year. This suggests a possible upside of 20.3% from the stock's current price. View Analyst Price Targets for NeoGenomics.
What is the consensus analysts' recommendation for NeoGenomics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NeoGenomics.
Has NeoGenomics been receiving favorable news coverage?
Media coverage about NEO stock has been trending very negative recently, according to InfoTrie. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. NeoGenomics earned a daily sentiment score of -3.2 on InfoTrie's scale. They also gave news stories about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for NeoGenomics.
Are investors shorting NeoGenomics?
NeoGenomics saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 5,500,000 shares, an increase of 13.2% from the August 30th total of 4,860,000 shares. Based on an average trading volume of 863,900 shares, the short-interest ratio is presently 6.4 days. Approximately 5.6% of the shares of the stock are sold short. View NeoGenomics' Current Options Chain.
Who are some of NeoGenomics' key competitors?
Some companies that are related to NeoGenomics include Eurofins Scientific (ERFSF), Neurocrine Biosciences (NBIX), ABIOMED (ABMD), Avantor (AVTR), FSD Pharma (FSDDF), Bausch Health Companies (BHC), IPSEN S A/S (IPSEY), Masimo (MASI), Icon (ICLR), BIO-TECHNE (TECH), Novocure (NVCR), Molina Healthcare (MOH), Teva Pharmaceutical Industries (TEVA), Recordati (RCDTF) and Perrigo (PRGO).
What other stocks do shareholders of NeoGenomics own?
Who are NeoGenomics' key executives?
NeoGenomics' management team includes the folowing people:
- Mr. Douglas M. VanOort, Chairman & CEO (Age 64)
- Ms. Sharon A. Virag, Chief Financial Officer (Age 52)
- Dr. Lawrence M. Weiss M.D., Chief Scientific Officer (Age 62)
- Mr. William Bishop Bonello, Chief Strategy & Corp. Devel. Officer and Director of Investor Relations (Age 54)
- Mr. George A. Cardoza, Pres of Pharma Services Division (Age 57)
Who are NeoGenomics' major shareholders?
NeoGenomics' stock is owned by many different of retail and institutional investors. Top institutional investors include Summit Creek Advisors LLC (0.35%), State of Alaska Department of Revenue (0.08%), Robeco Institutional Asset Management B.V. (0.08%), CIBC Private Wealth Group LLC (0.07%), Envestnet Asset Management Inc. (0.04%) and Campbell & CO Investment Adviser LLC (0.02%). Company insiders that own NeoGenomics stock include Electric Co General, George Cardoza, Jennifer Balliet, Kevin C Johnson, Lynn A Tetrault, Raymond R Hipp, Robert J Shovlin, Steven A Ross, Steven C Jones and William Bonello. View Institutional Ownership Trends for NeoGenomics.
Which major investors are selling NeoGenomics stock?
NEO stock was sold by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V. and CIBC Private Wealth Group LLC. Company insiders that have sold NeoGenomics company stock in the last year include Electric Co General, George Cardoza, Jennifer Balliet, Kevin C Johnson, Lynn A Tetrault, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello. View Insider Buying and Selling for NeoGenomics.
Which major investors are buying NeoGenomics stock?
NEO stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, HMS Capital Management LLC, Summit Creek Advisors LLC, Juncture Wealth Strategies LLC, Campbell & CO Investment Adviser LLC, Fox Run Management L.L.C., Nisa Investment Advisors LLC and Envestnet Asset Management Inc.. View Insider Buying and Selling for NeoGenomics.
How do I buy shares of NeoGenomics?
Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is NeoGenomics' stock price today?
One share of NEO stock can currently be purchased for approximately $20.42.
How big of a company is NeoGenomics?
NeoGenomics has a market capitalization of $2.12 billion and generates $276.74 million in revenue each year. The medical research company earns $2.64 million in net income (profit) each year or $0.13 on an earnings per share basis. NeoGenomics employs 1,500 workers across the globe.View Additional Information About NeoGenomics.
What is NeoGenomics' official website?
How can I contact NeoGenomics?
NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]
MarketBeat Community Rating for NeoGenomics (NASDAQ NEO)
MarketBeat's community ratings are surveys of what our community members think about NeoGenomics and other stocks. Vote "Outperform" if you believe NEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
